Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GALR3 | O60755 | 1/20 | 0.43 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.43 |
| ▸ | GPR183 | P32249 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12722501 | 1.00 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNAKMT2AMEN1NPC1 | |
| SCHEMBL15596706 | 0.97 | SMN1; SMN2 (0.43) | SMN1; SMN2LMNAKMT2AMEN1NPC1 | |
| SCHEMBL3412240 | 0.97 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNAKMT2AMEN1NPC1 | |
| SCHEMBL15596784 | 0.94 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAKMT2AMEN1NPC1 | |
| SCHEMBL12722376 | 0.91 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAKMT2AMEN1NPC1 | |
| SCHEMBL15596698 | 0.91 | APP (0.48) | SMN1; SMN2LMNAKMT2AMEN1NPC1 | |
| SCHEMBL15596646 | 0.89 | SMN1; SMN2 (0.42) | SMN1; SMN2LMNAKMT2AMEN1NPC1 | |
| SCHEMBL23867656 | 0.89 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNAKMT2AMEN1NPC1 | |
| SCHEMBL1627514 | 0.89 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNAKMT2AMEN1NPC1 | |
| SCHEMBL21511186 | 0.89 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAKMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744906-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | LANTHEUS MEDICAL IMAGING, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20210300878-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-20210300878-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| EP-3385253-B1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING INC (US) | 2021-04-07 | — | — | EP | disclosed |
| EP-3385253-B1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING INC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10889550-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-10889550-B2 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20200230264-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | LANTHEUS MEDICAL IMAGING, INC. (US) | 2020-07-23 | — | — | US | disclosed |
| EP-2257315-B1 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING INC (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-2257315-B1 | CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING | LANTHEUS MEDICAL IMAGING INC (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-1713512-A4 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080112884-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-20080112884-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-20080112884-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-7344702-B2 | Contrast agents for myocardial perfusion imaging | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| US-7344702-B2 | Contrast agents for myocardial perfusion imaging | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| US-7344702-B2 | Contrast agents for myocardial perfusion imaging | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1713512-A2 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | Bristol-Myers Squibb Pharma Company (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005079391-A2 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050191238-A1 | Contrast agents for myocardial perfusion imaging | LANTHEUS MEDICAL IMAGING, INC. | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080112884-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | SMN1; SMN2 2969/4885LMNA 3348/4885KMT2A 4432/4885 |
| US-20050191238-A1 | Contrast agents for myocardial perfusion imaging | TNNI3, TNNT2, FABP3 | SMN1; SMN2 2969/4885LMNA 3348/4885KMT2A 4432/4885 |
| US-20200230264-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | FABP3, TNNI3, TNNT2 | SMN1; SMN2 699/4885LMNA 1449/4885KMT2A 4341/4885 |
| US-20210300878-A1 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING | TNNI3, TNNT2, FABP3 | SMN1; SMN2 2969/4885LMNA 3348/4885KMT2A 4432/4885 |
| US-11744906-B2 | Compositions, methods, and systems for the synthesis and use of imaging agents | FABP3, TNNI3, TNNT2 | SMN1; SMN2 699/4885LMNA 1449/4885KMT2A 4341/4885 |
| US-10889550-B2 | Contrast agents for myocardial perfusion imaging | TNNI3, TNNT2, FABP3 | SMN1; SMN2 2969/4885LMNA 3348/4885KMT2A 4432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.